丙型肝炎病毒感染：寻找无干扰素治疗方案。
Hepatitis C virus infection: looking for interferon free regimens.
作者信息
González-Moreno J, Payeras-Cifre A
机构信息
Internal Medicine-Infectious Diseases Department, Hospital Son Llàtzer, Carretera de Manacor, Km 4, 07198 Palma de Mallorca, Spain.
出版信息
ScientificWorldJournal. 2013 Apr 9;2013:825375. doi: 10.1155/2013/825375. Print 2013.
Abstract
Recent developments of new drugs' combinations are changing the treatment paradigm in hepatitis C virus infection. Due to the side effect profile of pegylated interferons, interferon-sparing regimens have become the main target in chronic hepatitis C treatment research. Recent proofs of concept studies have suggested that cure of chronic hepatitis C can be achieved without interferon. The purpose of this paper is to provide an overview of the clinical results recently reported for the treatment of hepatitis C virus infection with interferon-free regimens, focusing on the most promising new compounds and combinations.
摘要
新型药物组合的最新进展正在改变丙型肝炎病毒感染的治疗模式。由于聚乙二醇化干扰素的副作用，避免使用干扰素的治疗方案已成为慢性丙型肝炎治疗研究的主要目标。最近的概念验证研究表明，不使用干扰素也可以治愈慢性丙型肝炎。本文旨在概述最近报道的使用无干扰素方案治疗丙型肝炎病毒感染的临床结果，重点关注最有前景的新化合物和组合。
相似文献
1
Hepatitis C virus infection: looking for interferon free regimens.
ScientificWorldJournal. 2013 Apr 9;2013:825375. doi: 10.1155/2013/825375. Print 2013.
2
Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Expert Rev Gastroenterol Hepatol. 2015 Mar;9(3):277-88. doi: 10.1586/17474124.2015.1001742. Epub 2015 Jan 29.
3
[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Orv Hetil. 2014 Mar;155 Suppl:3-24. doi: 10.1556/OH.2013.29893.
4
Novel interferons for treatment of hepatitis C virus.
Clin Liver Dis. 2009 Aug;13(3):351-63. doi: 10.1016/j.cld.2009.05.004.
5
[Antiviral treatment of hepatitis C virus infection].
Rev Med Interne. 1999 Aug;20 Suppl 3:331s-340s. doi: 10.1016/s0248-8663(99)80505-0.
6
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
Clin Liver Dis. 2013 Feb;17(1):93-103. doi: 10.1016/j.cld.2012.09.001.
7
Treatment of chronic hepatitis C virus infection.
Ann Pharmacother. 2000 Oct;34(10):1156-64. doi: 10.1345/aph.10017.
8
[New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
Orv Hetil. 2010 Dec 12;151(50):2045-56. doi: 10.1556/OH.2010.29011.
9
Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.
World J Gastroenterol. 2015 Jun 28;21(24):7412-26. doi: 10.3748/wjg.v21.i24.7412.
10
Protease inhibitors: silver bullets for chronic hepatitis C infection?
Cleve Clin J Med. 2012 Mar;79(3):213-22. doi: 10.3949/ccjm.79a.11082.
引用本文的文献
1
ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs).
Asian Pac J Cancer Prev. 2023 Jan 1;24(1):149-155. doi: 10.31557/APJCP.2023.24.1.149.
2
Exposure to aflatoxin B and associated risk factors in hepatitis C patients in cosmopolitan city of Pakistan: facility-based study.
Pan Afr Med J. 2021 Dec 21;40:247. doi: 10.11604/pamj.2021.40.247.23396. eCollection 2021.
3
New treatments for chronic hepatitis C: an overview for paediatricians.
World J Gastroenterol. 2014 Nov 21;20(43):15965-74. doi: 10.3748/wjg.v20.i43.15965.
4
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
Can J Gastroenterol Hepatol. 2014 Sep;28(8):445-51. doi: 10.1155/2014/549624.
本文引用的文献
1
Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 Jan 29.
2
Exploratory study of oral combination antiviral therapy for hepatitis C.
N Engl J Med. 2013 Jan 3;368(1):45-53. doi: 10.1056/NEJMoa1208809.
3
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.
4
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Antimicrob Agents Chemother. 2013 Mar;57(3):1312-22. doi: 10.1128/AAC.02239-12. Epub 2012 Dec 28.
5
Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Curr Opin Infect Dis. 2013 Feb;26(1):50-7. doi: 10.1097/QCO.0b013e32835c2027.
6
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
J Hepatol. 2013 Apr;58(4):655-62. doi: 10.1016/j.jhep.2012.09.037. Epub 2012 Nov 23.
7
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12. Epub 2012 Aug 6.
8
New pharmacotherapy for hepatitis C.
Clin Pharmacol Ther. 2012 Sep;92(3):294-305. doi: 10.1038/clpt.2012.103. Epub 2012 Aug 1.
9
Hepatitis C therapy in non-genotype 1 patients: the near future.
J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x.
10
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.
Lancet Infect Dis. 2012 Sep;12(9):717-28. doi: 10.1016/S1473-3099(12)70060-9. Epub 2012 May 29.
Zotero 插件